MI SB0809

Amends the health care false claims act to exempt rebates or discounts from drug manufacturers to consumers for administration or use of drugs, including cost-sharing requirements for injection, infusion, or similar application methods.

Permits monetary payments from drug manufacturers to consumers, their health professionals, or contracted vendors for health care services required or recommended by a drug's prescribing information.

Defines "qualified drug" as any drug with FDA approval to treat multiple sclerosis.

Specifies covered health care services including cardiac monitoring, blood tests, liver function tests, eye exams, pulmonary function tests, vaccinations, and other FDA-approved services.

Takes effect immediately upon passage on December 29, 2020.